Tag: Ampio Pharmaceuticals Inc (NYSEAMERICAN: AMPE)


Ampio Pharmaceuticals Inc (NYSEAMERICAN: AMPE) Obtains Sanction to Swell Registration of its AP-019 Phase II Study to India

Ampio Pharmaceuticals Inc (NYSEAMERICAN: AMPE), a biopharmaceutical company engrossed on the progression of immunology-based treatments for established demagogic circumstances, today proclaimed that it received regulatory sanction to swell registration of its AP-019 Phase II study to India. The study will employ inhaled Ampion™ to treat those in misery from respirational suffering due […]